Methods for increasing neural plasticity by contacting a neuronal cell with a non-hallucinogenic analog of a psychedelic compound, including analogs of DMT
Transdermal patch with composition for transdermal delivery of at least one cationic active agent, including indole compounds such as N,N-DMT
Disclosed are compositions containing two purified toad secretion tryptamines chosen from the following 5-MeO-DMT, 5-MeO-NMT, 5-Methoxytryptamine, bufobutanoic Acid, bufobutarginine, bufoserotonin A, bufoserotonin B, bufoserotonin C, bufotenidine, bufotenin, bufotenin Oxide, bufotenine-O-Sulphate, bufoviridine, dET, dMT, n-Acetylserotonin, n’-Formylserotonin, n-Methylserotonin, o-Methylbufoviridine, serotonin, tryptamine, and bufopyramide or the salts of these toad secretion tryptamines. The disclosure also relates to formulations, including pharmaceutical formulations, of such a composition and an excipient. Pharmaceutical formulation further containing a therapeutically effective amount of a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, or a purified terpene a disclosed. Also disclosed are methods of regulating the activity of a neurotransmitter receptor and methods of treating a psychological disorder, a compulsive disorder, or a depressive disorder.
Methods of treating mucosal inflammation in the gastrointestinal tract, by administering 5-HT7 receptor antagonist, including N,N-DMT
Methods for controlling rodents by contacting the rodents with a compound which is a ligand for an olfactory TAAR receptor, including 5-MeO-DMT
Methods for extracting a target alkaloid from a mixture of species, by using an ionic liquid as an extracting solvent, including for N,N-DMT and 5-MeO-DMT
Compositions of an oxidative phosphorylation inhibitor, ionophore, or AMPK activator; an anti-inflammatory agent; and a serotonergic agent, including N,N-DMT and 5-MeO-DMT
Pharmaceutical compositions of a AMPK activator and a serotonergic agent, the serotonergic agent including N,N-DMT and 5-MeO-DMT
Methods of treating a non-infectious disease with combination of methylsulfonylmethane, glucosamine, L-glycine, and vitamin B12, and optionally additional agent, e.g., 5-MeO-DMT
A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).